Your browser doesn't support javascript.
loading
Role of Hippo pathway dysregulation from gastrointestinal premalignant lesions to cancer.
Schiavoni, Giulia; Messina, Beatrice; Scalera, Stefano; Memeo, Lorenzo; Colarossi, Cristina; Mare, Marzia; Blandino, Giovanni; Ciliberto, Gennaro; Bon, Giulia; Maugeri-Saccà, Marcello.
Affiliation
  • Schiavoni G; Clinical Trial Center, Biostatistics and Bioinformatics Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Messina B; Clinical Trial Center, Biostatistics and Bioinformatics Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Scalera S; SAFU Laboratory, Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Memeo L; Pathology Unit, Mediterranean Institute of Oncology, Viagrande, Italy.
  • Colarossi C; Pathology Unit, Mediterranean Institute of Oncology, Viagrande, Italy.
  • Mare M; Medical Oncology Unit, Mediterranean Institute of Oncology, Viagrande, Italy.
  • Blandino G; Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy.
  • Ciliberto G; Translational Oncology Research Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Bon G; Scientific Directorate, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Maugeri-Saccà M; Cellular Network and Molecular Therapeutic Target Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy. giulia.bon@ifo.it.
J Transl Med ; 22(1): 213, 2024 02 29.
Article in En | MEDLINE | ID: mdl-38424512
ABSTRACT

BACKGROUND:

First identified in Drosophila melanogaster, the Hippo pathway is considered a major regulatory cascade controlling tissue homeostasis and organ development. Hippo signaling components include kinases whose activity regulates YAP and TAZ final effectors. In response to upstream stimuli, YAP and TAZ control transcriptional programs involved in cell proliferation, cytoskeletal reorganization and stemness. MAIN TEXT While fine tuning of Hippo cascade components is essential for maintaining the balance between proliferative and non-proliferative signals, pathway signaling is frequently dysregulated in gastrointestinal cancers. Also, YAP/TAZ aberrant activation has been described in conditions characterized by chronic inflammation that precede cancer development, suggesting a role of Hippo effectors in triggering carcinogenesis. In this review, we summarize the architecture of the Hippo pathway and discuss the involvement of signaling cascade unbalances in premalignant lesions of the gastrointestinal tract, providing a focus on the underlying molecular mechanisms.

CONCLUSIONS:

The biology of premalignant Hippo signaling dysregulation needs further investigation in order to elucidate the evolutionary trajectories triggering cancer inititation and develop effective early therapeutic strategies targeting the Hippo/YAP pathway.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hippo Signaling Pathway / Neoplasms Limits: Animals Language: En Journal: J Transl Med Year: 2024 Document type: Article Affiliation country: Italia Country of publication: Reino Unido

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hippo Signaling Pathway / Neoplasms Limits: Animals Language: En Journal: J Transl Med Year: 2024 Document type: Article Affiliation country: Italia Country of publication: Reino Unido